Previously, we found that RRM2 is upregulated in ER− and drug-resistant breast cancer cells, rationalizing our hypothesis of targeting ribonucleotide reductase for ER+ as well as ER− breast cancer treatment [12,13,14]. This evidence concerns the gene ESR1 and breast cancer.